More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.92B
EPS
-1.41
P/E ratio
--
Price to sales
2.32
Dividend yield
--
Beta
0.541406
Previous close
$7.61
Today's open
$7.63
Day's range
$7.41 - $7.74
52 week range
$6.23 - $11.22
show more
CEO
Jon P. Stonehouse
Employees
435
Headquarters
Durham, NC
Exchange
Nasdaq Global Select
Shares outstanding
257299269
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
BioCryst Presents New Real-World Evidence Showing Reduced Angioedema-Related Medical Visits After Switching to ORLADEYO® (berotralstat) at ACAAI 2026 Annual Scientific Meeting
— Two real-world studies demonstrate reductions in healthcare resource utilization in HAE patients who initiated or switched to ORLADEYO ® from another prophylactic therapy —
GlobeNewsWire • Nov 13, 2026

4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth
TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.
Zacks Investment Research • Nov 10, 2026

BioCryst Pharmaceuticals Q3 Earnings Call Highlights
BioCryst Pharmaceuticals NASDAQ: BCRX reported third-quarter results marked by growth in ORLADEYO revenue, higher profitability and progress across its hereditary angioedema, or HAE, portfolio, while maintaining its full-year ORLADEYO revenue outlook following a specialty-pharmacy transition.
MarketBeat • Nov 4, 2026

BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst
BioCryst Pharmaceuticals delivered Q3 2026 results ahead of expectations, maintaining 2026 guidance and highlighting Orladeyo's ongoing growth in a competitive HAE market. BCRX's valuation appears modest at ~3.5x forward P/S and ~11x forward P/E (excluding IPR&D), but future upside depends on pipeline execution, especially navenibart. Management pivots to external innovation, targeting >$1bn revenues by 2030 with Orladeyo, navenibart, and BCX17725, while royalty burdens are set to ease after 2029.
Seeking Alpha • Nov 4, 2026

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2026 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Nick Wilder - Manager of Investor Relations Charles Gayer - CEO, President & Director Babar Ghias - CFO & Head of Corporate Development Sandeep Menon - Chief Research & Development Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Laura Chico - Wedbush Securities Inc., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Stacy Ku - TD Cowen, Research Division Jeremiah Lorentz - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the BioCryst Third Quarter 2026 Earnings Call.
Seeking Alpha • Nov 4, 2026

BioCryst Reports Third Quarter 2026 Financial Results
— Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — — Improved Non-GAAP operating expense guidance to $415 to $425 million — — Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended September 30, 2026, and provided a business update.
GlobeNewsWire • Nov 4, 2026

BioCryst Pharmaceuticals (BCRX) Surpasses Q3 Earnings and Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.06 per share a year ago.
Zacks Investment Research • Nov 4, 2026

BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 8:30 a.m.
GlobeNewsWire • Nov 4, 2026

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
The consensus price target hints at a 137.9% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research • Oct 30, 2026

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that four abstracts from its hereditary angioedema (HAE) portfolio have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting taking place in Phoenix, Arizona, November 12-16.
GlobeNewsWire • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell BioCryst Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.